ARWR
ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$66.48
−1.86%Next report
Analyst consensus
- Next report date
- Nov 24, 2026
- EPS estimate
- -$1.59
- Revenue estimate
- $59.4M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$1.36
- EPS estimate
- -$1.28
- Revenue actual
- $75.3M
- Revenue estimate
- $44.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 10
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -27.4%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $112
- PT range
- $95 – $126
- Analysts
- 9
9 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$1.28 | -$1.36 | Miss -6.25% | $75.3M |
| May 7, 2026 | -$1.18 | -$0.93 | Beat 21.19% | $73.7M |
| Feb 5, 2026 | $0.60 | $0.22 | Miss -63.33% | $264.0M |
| Nov 25, 2025 | -$0.11 | -$0.18 | Miss -61.33% | $256.5M |
| Aug 7, 2025 | -$0.94 | -$1.26 | Miss -34.04% | $27.8M |
| Nov 26, 2024 | -$1.05 | -$1.38 | Miss -31.43% | $3.6M |
| Aug 8, 2024 | -$0.58 | -$1.38 | Miss -137.93% | — |
| May 9, 2024 | -$0.06 | -$1.02 | Miss -1600.00% | — |
| Nov 29, 2023 | -$0.70 | -$1.03 | Miss -47.14% | $16.1M |
| May 2, 2023 | -$0.64 | $0.45 | Beat 170.31% | $146.3M |
| Feb 6, 2023 | $1.14 | -$0.39 | Miss -134.21% | $62.5M |
| Nov 28, 2022 | -$0.57 | -$0.81 | Miss -42.11% | $31.6M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 24, 2026